Psychedelic Chemistry, Magic Mushrooms, Kratom, Gray Market Research Chemicals, Vape Shops | Andrew Chadeayne | 231
Mind & Matter · Nick Jikomes and Andrew Chadeayne
Audio is streamed directly from the publisher (api.substack.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Wide release date: May 25, 2025
Episode Summary: CaaMTech CEO Dr. Andrew Chadeayne, discusses the chemistry of magic mushrooms and other psychedelics, their potential therapeutic applications, and the challenges of commercializing them in a shifting biotech market. The conversation delves into the complexities of magic mushroom composition, debunking myths like "lemon tekking," and uncovers the booming, unregulated alternative products industry, including kratom and synthetic psilocybin analogs sold in vape shops.
About the guest: Andrew Chadeayne, PhD is a chemist who also holds a law degree, specializing in patent law. He is the founder and CEO of CaaMTech, a startup specializing in the development of novel psychedelic compounds. Chadeayne collaborates with academic labs to advance psychedelic science while navigating the commercial landscape.
Discussion Points:
* Psilocybin is a prodrug converted to psilocin, but magic mushrooms contain other psychoactive molecules like beta-carbolines, which may enhance effects by inhibiting degradation.
* Chadeayne’s team develops psilocin prodrugs to shorten psychedelic trips, making clinical administration more manageable without altering effects.
* The "lemon tek" myth—that lemon juice converts psilocybin to psilocin—is false; it enhances absorption by extracting compounds, not altering chemistry.
* Magic mushroom bruising indicates psilocin degradation, as oxidized psilocin forms blue, inactive dimers.
* The multi-billion dollar alternative products industry sells kratom and synthetic psilocybin analogs, often mislabeled, in vape shops, raising safety and regulatory concerns.
* Kratom’s minor alkaloid, 7-hydroxymitragynine, is ~40x more potent than morphine.
* Non-hallucinogenic serotonin 2A agonists, like those developed by CaaMTech’s spinout, show promise for conditions like migraines without requiring a psychedelic trip.
Related episode:
* M&M 71: Chemistry of Magic Mushrooms, DMT Analogues, Entourage Effects in Cannabis & Fungi, Novel Psychedelic Medicines, Psychedelic Startups | Andrew Chadeayne
*Not medical advice.
* Full audio version: [Apple] [Spotify] [Elsewhere]
* Full video version: [YouTube] [Rumble]
* Support M&M if you find value in this content.
* Episode transcript below.
Episode Chapters:
00:00:00 Intro00:02:21 Guest Background & CaaMTech Overview00:08:55 Psychedelic Chemistry & Magic Mushroom Molecules00:15:38 Developing New Psychedelic Prodrugs00:22:14 Academic Collaborations & Science Funding00:29:13 Non-Hallucinogenic Psychedelic Derivatives00:35:53 Debunking Psilocybin Myths00:44:16 Gray Market & Magic Mushroom Chocolate Bars00:54:33 Kratom & Alternative Products Industry01:03:00 7-Hydroxymitragynine Risks & Regulation01:12:51 Industry Self-Regulation & Future Directions01:22:17 Therapeutic Potential Without the Trip01:30:29 CaaMTech’s Future & Scientific Integrity
Full AI-generated transcript below. Beware of typos & mistranslations!